Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. We have assembled a seasoned team with extensive expertise in drug discovery and development in endocrine G-protein coupled receptors (GPCRs) and built a highly productive drug discovery organization.
We have discovered a pipeline of oral nonpeptide (small molecule) new chemical entities that target peptide GPCRs to treat a variety of rare endocrine diseases where treatment options have significant efficacy, safety and/or tolerability limitations.
Our lead product candidate, CRN00808, is currently in clinical development for the treatment of acromegaly, and we are advancing additional product candidates through preclinical studies in parallel.
Our vision is to build the leading endocrine company which consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives.
Completed $117 million IPO on NASDAQ
Alan Krasner joined as CMO
Reported initial results from Phase 1 study of CRN00808
Completed $63.5 million Series B financing
Marc Wilson joined as CFO
Initiated Phase 1 Study of CRN00808 for acromegaly
Awarded $2.4 million in SBIR grants for discovery of small molecule therapies targeting Cushing’s disease and hyperinsulinemic hypoglycemia
Awarded $2.8 million SBIR Phase IIb grant for development of small molecule therapy for acromegaly
Appointed Ajay Madan as VP, Development
Completed $40.0 million Series A financing
Awarded $1.5 million Phase II SBIR grant for discovery of kisspeptin antagonists for women’s health
Awarded $2.2 million Phase II SBIR grant for discovery and development of a small molecule therapy for acromegaly
Awarded first of two grants from Michaelson Prize and Grant Program to investigate veterinary reproductive health
First Crinetics laboratory opened
Phase 1 Grant
Awarded Phase I SBIR grant to study GPCR biosensors
Crinetics is incorporated